hepatogenous diabetes
Conditions
Interventions
We investigate the glucose profile of patients using continuous glucose monitoring (CGM) before initiating treatment with imeglimin.
Sponsors
Miyatsuka Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1, Liver cirrhosis 2, Child-Pugh A or B 3, HbA1c levels between 6.5% and 10.0% from 4 to 12 weeks before the beginning of this trial 4, Patients scheduled to receive imeglimin who are eligible for its use
Exclusion criteria
Exclusion criteria: 1, Before or after surgery or severe trauma 2, Alcohol consumption more than 30 g/day in male, more than 20 g/day in female 3, Liver cirrhosis Child-Pugh C 4, Presence of malignant tumors 5, Severe anemia Hb less than 7 g/dL 6, Chronic kidney disease eGFR less than 45 mL/min/1.73 m2 7, Patients using implanted medical devices 8, Patients who cannot fully understand the explanaition because of mental developmental retardation or linguistic problems 9, Patients deemed by the principal investigator or study team to be unable to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Indicators of blood glucose variability before and after imeglimin administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1, Change in HbA1c 2, Changes in body weight, fat mass, muscle mass, and lean body mass 3, Change in C-peptide 4, Presence or absence of severe hypoglycemia | — |
Contacts
Public ContactNagisa Aoki
Diabetes, Endocrinology, and Metabolism, School of Medicine, Kitasato University
Outcome results
None listed